Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPICI: Treatment Pause vs Continuation in mRCC
NCT05219318Phase 3Active, not recruiting
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jan 2023
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Proportion of participants without progression at 12 months. Started Jan 2023; status: active, not recruiting.
02
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT05219318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05219318.